Restoration ofmiR-101 suppresses lung tumorigenesis through inhibition of DNMT3a-dependent DNA methylation

Cell Death and Disease

Volumn 5, Issue 9, 2014, Pages

  Yan, F ^a   Shen, N ^a   Pang, J ^a   Xie, D ^b   Deng, B ^b   Molina, J R ^b   Yang, P ^b   Liu, S ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; DNA METHYLTRANSFERASE 3A; LUCIFERASE; MICRORNA 101; UVOMORULIN; DNA (CYTOSINE 5) METHYLTRANSFERASE; MICRORNA; MIRN101 MICRORNA, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING SITE; CANCER CELL; CELL GROWTH; CELL MIGRATION; CONTROLLED STUDY; DNA METHYLATION; DOWN REGULATION; ENZYME ACTIVITY; FEMALE; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LUNG CANCER CELL LINE; LUNG CARCINOGENESIS; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; TIGHT JUNCTION; TUMOR GROWTH; TUMOR REGRESSION; TUMOR XENOGRAFT; ANIMAL; C57BL MOUSE; CARCINOGENESIS; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; LUNG TUMOR; MALE; METABOLISM; NON SMALL CELL LUNG CANCER; PATHOLOGY;

ANIMALS; CARCINOGENESIS; CARCINOMA, NON-SMALL-CELL LUNG; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; DNA METHYLATION; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; MALE; MICE; MICE, INBRED C57BL; MICRORNAS;

EID: 84920273128     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2014.380     Document Type: Article

References (56)

1. Choong NW, Ma PC, Salgia R. Therapeutic targeting of receptor tyrosine kinases in lung cancer. Expert Opin Ther Targets 2005; 9: 533-559.
2. Jafri NF, Ma PC, Maulik G, Salgia R. Mechanisms of metastasis as related to receptor tyrosine kinases in small-cell lung cancer. J Environ Pathol Toxicol Oncol 2003; 22: 147-165.
3. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ et al. Cancer statistics 2007CA Cancer J Clin 2007; 57: 43-66.
4. Jones PA, Laird PW. Cancer epigenetics comes of age. Nat Genet 1999; 21: 163-167.
5. Baylin SB, Herman JG. DNA hypermethylation in tumorigenesis: epigenetics joins genetics. Trends Genet 2000; 16: 168-174.
6. Mizuno S, Chijiwa T, Okamura T, Akashi K, Fukumaki Y, Niho Y et al. Expression of DNA methyltransferases DNMT1, 3A, and 3B in normal hematopoiesis and in acute and chronic myelogenous leukemia. Blood 2001; 97: 1172-1179.
7. Fabbri M, Garzon R, Cimmino A, Liu Z, Zanesi N, Callegari E et al. MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proc Natl Acad Sci USA 2007; 104: 15805-15810.
8. Kase S, Sugio K, Yamazaki K, Okamoto T, Yano T, Sugimachi K et al. Expression of E-cadherin and beta-catenin in human non-small cell lung cancer and the clinical significance. Clin Cancer Res 2000; 6: 4789-4796.
9. Tsumura A, Hayakawa T, Kumaki Y, Takebayashi S, Sakaue M, Matsuoka C et al. Maintenance of self-renewal ability of mouse embryonic stem cells in the absence of DNA methyltransferases Dnmt1, Dnmt3a and Dnmt3b. Gene Cells 2006; 11: 805-814.
10. Chen T, Ueda Y, Dodge JE, Wang Z, Li E. Establishment and maintenance of genomic methylation patterns in mouse embryonic stem cells by Dnmt3a and Dnmt3b. Mol Cell Biol 2003; 23: 5594-5605.
11. Iliopoulos D, Guler G, Han SY, Johnston D, Druck T, McCorkell KA et al. Fragile genes as biomarkers: epigenetic control of WWOX and FHIT in lung, breast and bladder cancer. Oncogene 2005; 24: 1625-1633.
12. Fabbri M, Iliopoulos D, Trapasso F, Aqeilan RI, Cimmino A, Zanesi N et al. WWOX gene restoration prevents lung cancer growth in vitro and in vivo. Proc Natl Acad Sci USA 2005; 102: 15611-15616.
13. Garzon R, Liu S, Fabbri M, Liu Z, Heaphy CE, Callegari E et al. MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene re-expression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1. Blood 2009; 113: 6411-6418.
14. Sandoval J, Mendez-Gonzalez J, Nadal E, Chen G, Carmona FJ, Sayols S et al. A prognostic DNA methylation signature for stage I non-small-cell lung cancer. J Clin Oncol 2013; 31: 4140-4147.
15. Toyooka S, Matsuo K, Gazdar AF. DNA methylation in lung cancer. N Engl J Med 2008; 358: 2513.
16. Zhao Z, Wu Q, Cheng J, Qiu X, Zhang J, Fan H et al. Depletion of DNMT3A suppressed cell proliferation and restored PTEN in hepatocellular carcinoma cell. J Biomed Biotechnol 2010 737535.
17. Bentwich I, Avniel A, Karov Y, Aharonov R, Gilad S, Barad O et al. Identification of hundreds of conserved and nonconserved human microRNAs. Nat Genet 2005; 37: 766-770.
18. Berezikov E, Guryev V, van de Belt J, Wienholds E, Plasterk RH, Cuppen E et al. Phylogenetic shadowing and computational identification of human microRNA genes. Cell 2005; 120: 21-24.
19. Garzon R, Fabbri M, Cimmino A, Calin GA, Croce CM. MicroRNA expression and function in cancer. Trends Mol Med 2006; 12: 580-587.
20. Pillai RS, Artus CG, Filipowicz W. Tethering of human Ago proteins to mRNA mimics the miRNA-mediated repression of protein synthesis. RNA 10: 1518-1525 2004.
21. Pillai R. S., Bhattacharyya SN, Artus CG, Zoller T, Cougot N, Basyuk E et al. Inhibition of translational initiation by Let-7 MicroRNA in human cells. Science 2005; 309: 1573-1576.
22. Pillai RS, Bhattacharyya SN, Filipowicz W. Repression of protein synthesis by miRNAs: how many mechanisms? Trends Cell Biol 2007; 17: 118-126.
23. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer 2006; 6: 857-866.
24. Peng Y, Dai Y, Hitchcock C, Yang X, Kassis ES, Liu L et al. Insulin growth factor signaling is regulated by microRNA-486, an underexpressed microRNA in lung cancer. Proc Natl Acad Sci USA 2013; 110: 15043-15048.
25. Hatley ME, Patrick DM, Garcia MR, Richardson JA, Bassel-Duby R, van Rooij E et al. Modulation of K-Ras-dependent lung tumorigenesis by MicroRNA-21. Cancer Cell 2010; 18: 282-293.
26. Braconi C, Huang N, Patel T. MicroRNA-dependent regulation of DNA methyltransferase-1 and tumor suppressor gene expression by interleukin-6 in human malignant cholangiocytes. Hepatology 2010; 51: 881-890.
27. Duursma AM, Kedde M, Schrier M, le Sage C, Agami R. miR-148 targets human DNMT3b protein coding region. RNA 2008; 14: 872-877.
28. Strillacci A, Valerii MC, Sansone P, Caggiano C, Sgromo A, Vittori L et al. Loss of miR-101 expression promotes Wnt/beta-catenin signalling pathway activation and malignancy in colon cancer cells. J Pathol 2013; 229: 379-389.
29. Varambally S, Cao Q, Mani RS, Shankar S, Wang X, Ateeq B et al. Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science 2008; 322: 1695-1699.
30. Thu KL, Chari R, Lockwood WW, Lam S, Lam WL. miR-101 DNA copy loss is a prominent subtype specific event in lung cancer. J Thorac Oncol 2011; 6: 1594-1598.
31. Schee K, Boye K, Abrahamsen TW, Fodstad O, Flatmark K. Clinical relevance of microRNA miR-21, miR-31, miR-92a, miR-101, miR-106a and miR-145 in colorectal cancer. BMC Cancer 2012; 12: 505.
32. Cho HM, Jeon HS, Lee SY, Jeong KJ, Park SY, Lee HY et al. microRNA-101 inhibits lung cancer invasion through the regulation of enhancer of zeste homolog 2. Exp Ther Med 2011; 2: 963-967.
33. Friedman JM, Liang G, Liu CC, Wolff EM, Tsai YC, Ye W et al. The putative tumor suppressor microRNA-101 modulates the cancer epigenome by repressing the polycomb group protein EZH2. Cancer Res 2009; 69: 2623-2629.
34. Ito S, D'Alessio AC, Taranova OV, Hong K, Sowers LC, Zhang Y et al. Role of Tet proteins in 5mC to 5hmC conversion, ES-cell self-renewal and inner cell mass specification. Nature 2010; 466: 1129-1133.
35. Ceteci F, Ceteci S, Karreman C, Kramer BW, Asan E, Gö tz R et al. Disruption of tumor cell adhesion promotes angiogenic switch and progression to micrometastasis in RAF-driven murine lung cancer. Cancer Cell 2007; 12: 145-159.
36. Sheikhnejad R, Zohri M, Shadmehr MB, Rahmani-Khalili M, Doozande N, Farsad Z et al. Detection of aberrant methylation of 10 genes in genomic DNA of lung tumors. Ann Oncol 2013; 24: 2705-2706.
37. Sulzer MA, Leers MP, van Noord JA, Bollen EC, Theunissen PH. Reduced E-cadherin expression is associated with increased lymph node metastasis and unfavorable prognosis in non-small cell lung cancer. Am J Respir Crit Care Med 1998; 157: 1319-1323.
38. Liu D, Huang C, Kameyama K, Hayashi E, Yamauchi A, Kobayashi S et al. E-cadherin expression associated with differentiation and prognosis in patients with non-small cell lung cancer. Ann Thorac Surg 2001; 71: 949-954.
39. Su H, Yang JR, Xu T, Huang J, Xu L, Yuan Y et al. MicroRNA-101, down-regulated in hepatocellular carcinoma, promotes apoptosis and suppresses tumorigenicity. Cancer Res 2009; 69: 1135-1142.
40. Bacher U, Haferlach C, Schnittger S, Kohlmann A, Kern W, Haferlach T et al. Mutations of the TET2 and CBL genes: novel molecular markers in myeloid malignancies. Ann Hematol 2010; 89: 643-652.
41. Liu S, Wu LC, Pang J, Santhanam R, Schwind S, Wu YZ et al. Sp1/NFkappaB/HDAC/ miR-29b regulatory network in KIT-driven myeloid leukemia. Cancer Cell 2010; 17: 333-347.
42. Robert MF, Morin S, Beaulieu N, Gauthier F, Chute IC, Barsalou A et al. DNMT1 is required to maintain CpG methylation and aberrant gene silencing in human cancer cells. Nat Genet 2003; 33: 61-65.
43. Yanaihara N, Caplen N, Bowman E, Seike M, Kumamoto K, Yi M et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 2006; 9: 189-198.
44. Navarro A, Diaz T, Gallardo E, Vinõlas N, Marrades RM, Gel B et al. Prognostic implications of miR-16 expression levels in resected non-small-cell lung cancer. J Surg Oncol 2011; 103: 411-415.
45. Hennessey PT, Sanford T, Choudhary A, Mydlarz WW, Brown D, Adai AT et al. Serum microRNA biomarkers for detection of non-small cell lung cancer. PLoS One 2012; 7: e32307.
46. Zheng D, Haddadin S, Wang Y, Gu LQ, Perry MC, Freter CE et al. Plasma microRNAs as novel biomarkers for early detection of lung cancer. Int J Clin Exp Pathol 2011; 4: 575-586.
47. Tang D, Shen Y, Wang M, Yang R, Wang Z, Sui A et al. Identification of plasma microRNAs as novel noninvasive biomarkers for early detection of lung cancer. Eur J Cancer Prev 2013; 22: 540-548.
48. Leidinger P, Keller A, Meese E. MicroRNAs-important molecules in lung cancer research. Front Genet 2011; 2: 104.
49. Banerjee R, Mani RS, Russo N, Scanlon CS, Tsodikov A, Jing X et al. The tumor suppressor gene rap1GAP is silenced by miR-101-mediated EZH2 overexpression in invasive squamous cell carcinoma. Oncogene 2011; 30: 4339-4349.
50. Ren G, Baritaki S, Marathe H, Feng J, Park S, Beach S et al. Polycomb protein EZH2 regulates tumor invasion via the transcriptional repression of the metastasis suppressor RKIP in breast and prostate cancer. Cancer Res 2012; 72: 3091-3104.
51. Kottakis F, Polytarchou C, Foltopoulou P, Sanidas I, Kampranis SC, Tsichlis PN et al. FGF-2 regulates cell proliferation, migration, and angiogenesis through an NDY1/KDM2BmiR-101-EZH2 pathway. Mol Cell 2011; 43: 285-298.
52. Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C, Sanda MG et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 2002; 419: 624-629.
53. Takawa M, Masuda K, Kunizaki M, Daigo Y, Takagi K, Iwai Y et al. Validation of the histone methyltransferase EZH2 as a therapeutic target for various types of human cancer and as a prognostic marker. Cancer Sci 2011; 102: 1298-1305.
54. Vire E, Brenner C, Deplus R, Blanchon L, Fraga M, Didelot C et al. The Polycomb group protein EZH2 directly controls DNA methylation. Nature 2006; 439: 871-874.
55. Xia Y, Chen Q, Zhong Z, Xu C, Wu C, Liu B et al. Down-regulation of miR-30c promotes the invasion of non-small cell lung cancer by targeting MTA1. Cell Physiol Biochem 2013; 32: 476-485.
56. Tomayko MM, Reynolds CP. Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother Pharmacol 1989; 24: 148-154.